ADCT:NYE-ADC Therapeutics SA (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 24.34

Change

+1.61 (+7.08)%

Market Cap

USD 1.74B

Volume

0.26M

Average Target Price

USD 49.60 (+103.78%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Company Website : http://www.adctherapeutics.com

Address : Biopole, Epalinges, Switzerland, 1066

Employees : 208

Fiscal Year End : September

Currency: USD

Country : USA

Technical Indicators

52 Week High : 56.59

Short Ratio : 12.67

52 Week Low : 21.51

Shorted Shares : 5,759,111

200 Day Moving Average : 30.67

Shorted Shares Previous Month : 4,435,524

50 Day Moving Average : 26.14

Shares Held By Insiders : 480.48%

Short Percentage : 8.00%

Shares Held by Institutions : 41.44%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.22 (-0.31%)

 USD163.29B 24.57 2.73
BHVN Biohaven Pharmaceutical Holdin..

+2.02 (+2.78%)

 USD4.70B N/A N/A
RCUS Arcus Biosciences, Inc

+0.76 (+2.34%)

 USD2.30B N/A N/A
MYOV Myovant Sciences Ltd

+0.47 (+2.75%)

 USD1.55B N/A N/A
ZYME Zymeworks Inc

+2.12 (+7.59%)

 USD1.29B 300.20 N/A
RFL Rafael Holdings, Inc

+0.56 (+1.39%)

 USD0.69B N/A N/A
CVM CEL-SCI Corporation

+1.05 (+6.67%)

 USD0.65B N/A N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
LCTX Lineage Cell Therapeutics, Inc

-0.16 (-6.56%)

 USD0.39B 3.63 N/A
AMPE Ampio Pharmaceuticals, Inc

-0.04 (-2.37%)

 USD0.33B 26.87 N/A

ETFs Containing ADCT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -34.20% 12% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.20% 12% F 2% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 1.74B 89% B+ 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 78% C+ 99% A+
Price/Book Ratio 5.20 54% F 20% F
Price / Cash Flow Ratio -10.34 79% C+ 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -110.28% 48% F 4% F
Return on Invested Capital -78.67% 43% F 2% F
Return on Assets -42.04% 39% F 1% F
Debt to Equity Ratio 32.19% 29% F 73% C
Technical Ratios  
Short Ratio 12.67 4% F 1% F
Short Percent 19.48% 8% F 25% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector